|
Mean (SD)
|
Placebo (n = 7)
|
Namilumab 150 mg (n = 7)
|
Namilumab 300 mg (n = 7)
|
Total (N = 21)
|
|---|
|
DAS28-ESR
|
4.7 (0.33)
|
4.9 (0.35)
|
4.4 (0.59)
|
4.7 (0.47)
|
|
DAS28-CRP
|
4.0 (0.35)
|
4.4 (0.33)
|
4.0 (0.62)
|
4.1 (0.46)
|
|
ESR, mm/hour
|
31.3 (7.43)
|
27.7 (5.94)
|
23.0 (8.06)
|
27.3 (7.66)
|
|
CRP, mg/liter
|
16.4 (25.09)
|
9.1 (6.42)
|
11.5 (10.44)
|
12.2 (14.91)
|
|
TJC (0–68)
|
6.6 (2.15)
|
10.0 (6.98)
|
9.6 (4.69)
|
8.7 (5.00)
|
|
SJC (0–66)
|
3.4 (1.4)
|
4.7 (2.14)
|
6.1 (5.3)
|
4.8 (3.42)
|
|
PGA for pain
|
54.6 (14.9)
|
58.4 (21.1)
|
50.1 (16.7)
|
54.3 (17.5)
|
|
PGA of DAS
|
42.4 (21.1)
|
59.9 (19.3)
|
43.3 (16.4)
|
39.5 (18.9)
|
-
CRP C-reactive protein, DAS disease activity score, ESR erythrocyte sedimentation rate, PGA patient global assessment, SD standard deviation, SJC swollen joint count, TJC tender joint count
